Drugs

Merck, known as MSD outside of the US and Canada, announced that it had opened a new secondary packaging facility to support production of vaccines and biologics, particularly for its immunotherapy portfolio, including Keytruda (pembrolizumab). In addition, the company broke ground for an inhaler production facility that will be used to manufacture ‘new generation’ inhaler
0 Comments
Partial operations give Samsung Biologics fresh GMP biomanufacturing capacity of 60,000 liters. Total capacity of the plant will reach 240,000 liters once fully open in the first half of next year. Swift growth Samsung Biologics facilities are located close to Incheon International airport. Operations at Plant 1 begun in 2015, followed by two additional plants
0 Comments
The research, conducted with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The company said the research findings details how this platform was used to express a malaria protein antigen that can be delivered intranasally and
0 Comments
The biotech has agreed a Letter of Intent with the State of Victoria in Australia to collaborate on the research and development of potential mRNA-based vaccines and therapies. As part of the partnership, the parties will establish a research and innovation center in Melbourne to facilitate the transition of encouraging academic research into clinical development.
0 Comments
Form Bio has been spun-out of Colossal Biosiences, which is a company that is focused on ‘de-extinction,’ having plans to resurrect extinct species, such as the woolly mammoth and thylacine (also known as the Tasmanian tiger). Through its work on the de-extinction process, Colossal developed software that combined artificial intelligence and biology. According to the
0 Comments
Boston-headquartered Ginkgo has significantly expanded its work in cell and gene therapy over the last few years, including a program to improve adeno-associated virus (AAV) manufacturing in partnership with Biogen, and a program to develop AAV capsids with altered tropism and immunogenicity in partnership with Selecta Biosciences. The field of nucleic acid therapeutics is a
0 Comments
Headquartered in Köln and founded in 2003, CEVEC Pharmaceuticals provides cell tech for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale: with a portfolio covering various platform technologies for gene therapy vectors, vector vaccines and complex recombinant proteins. This includes its Elevecta tech for AAV manufacturing, CAP Ad tech for RCA-free adenoviral vectors,
0 Comments
Lecanemab is an anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). Co-developed by Eisai and Biogen, the companies announced positive findings​​ on the drug from the Clarity AD phase 3 trial on September 27, with the results suggesting lecanemab can slow cognitive and functional decline
0 Comments
Lexington, Mass.-based LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. Its foundational platform technology, GeneRide, differs from traditional gene therapy in that it harnesses the cell’s natural DNA repair process to integrate a corrective gene directly
0 Comments
The cell and gene therapy contract development and manufacturing organization (CDMO), which specializes in lentiviral and retroviral vector manufacturing, said the latest phase of the buildout sees additional process development, analytical development, and quality control labs as well as GMP cell banking and GMP vector manufacturing suites with an expanded GMP warehouse at the facility. The
0 Comments
The Darmstadt, Germany headquartered business combined its existing contract development and manufacturing organization (CDMO) and contract testing services in February this year; that CTDMO offer forms part of the recently formed Life Science Services (LSS) division. The objective: the strengthening of its CDMO offering and speeding up future growth. Millipore CTDMO services span pre-clinical to
0 Comments
The Gilead company says the approval makes it the only cell therapy company with in-house viral vector manufacturing capabilities for both clinical trials and commercial products. Furthermore, it strengthens the company’s global CAR T-cell therapy manufacturing network as it sees growing demand for its blood cancer treatments. ‘This milestone is several years in the making’
0 Comments
Coronaviruses are enveloped viruses by nature, making them prime targets for the company’s flexible eVLP technology, says the company. A Phase 1a/1b study of two monovalent, variant-specific vaccine candidates has already generated human proof-of-concept data, demonstrating safety, tolerability and immunogenicity of the platform. Now, the multivalent version is targeting BA.4 and BA.5 as well as
0 Comments